Ken Griffin is betting on the castle 300 million pounds against the GSK pharmaceutical maker

Digest opened free editor

Rola Khaleda, FT editor, chooses her favorite stories in this weekly newsletter.

Citadel, the hedge fund, has a gift of 305 million pounds against GSK pharmaceutical makerThe biggest position against the company for more than a decade.

Billionaire Ken Griffin Hedgement Fund It revealed that it entered the net of the short center on Tuesday, when the betting value is 0.51 percent of the company’s shares, according to data from the financial behavior authority collected by the Provider Breakout Point.

The last time any company revealed a bet against the FTSE 100 drugs group in 2013, according to FCA disclosure.

GSK shares increased by 11 percent last month, as the pharmaceutical maker raised their long -term sales expectations and enacted A rare re -purchase process is 2 billion pounds Earlier this month. GSK has reported better profits than expected for strong sales of HIV and cancer drugs.

But the shares failed to compete, as the drug maker failed to raise investors around the new pipeline and vaccine pipelines, which need to replace HIV drugs when they face the patent shelf later in the contract. In the past five years, the shares of GSK have decreased by 15 percent, compared to the S& P 500 drugs, which increased by 45 percent.

Emma and Al -Mili, CEO of GSK, have already a battle against an active investor, when the Elliott Management Fund built a share of millions of pounds in the company in 2021. Elliot wondered whether Walmsley was the correct company of the company, given that it does not do so you have a background Scientific. It also pushed GSK to consider her work in Haleon Health. Which was later woven.

JPMorgan analysts said that the fourth quarter profits and the company’s 2025 directions were “positive”. But they added: “We believe that the market may also be wondering about the logic of re -purchase three years after the start of the HIV patent, with a pipeline in the late stage.” Barclays analysts also said that the re -purchase of shares is “unexpected.”

GSK shares collapsed in August 2022, when the drug claims appeared in the stomach. But when GSK settled the vast majority of cases for $ 2.2 billion in October last year, the shares did not return to their previous level.

The company also suffered from bad unexpected news for major producers. In 2022, GSK pulled its cancer drug from the United States market, after the experience of food and drug management requirements did not meet the drugs that obtained accelerated approval. After more studies, the company is now expecting the re -introduction of the drug by the organizer by July 2023.

ARexvy sales, its vaccine for the respiratory virus, known as RSV, decreased in the second half of last year because a consulting committee in the United States was unexpectedly recommended to its use.

Citadel is the world’s highest -performance hedge box according to LCC Investments, and is an investor in hedge funds. The company includes hundreds of trading teams that are betting on a wide range of assets, including stocks. Citadel runs the capital of the investor worth $ 65 billion from the beginning of the year, and increased 15.1 percent in 2024.

Citadel refused to comment because the company does not discuss its positions. GSK did not immediately respond to a request for comment.